Gilead Sciences Inc (NASDAQ: GILD), a biopharmaceutical company, had a "buy" rating before Saturday. Evercore ISI financial analysts issued a report on Saturday that reiterated that rating. As of now, Evercore ISI has a $90 price target on Gilead Sciences Inc. The Evercore ISI price objective has a potential upside of GSI as 23.71 percent from the current price.
Evercore is not the only financial institution to rethink their ranking of Gilead Sciences Inc. As recently as a research report that was released in late July, Piper Jaffray Cos. reduced their price target on GSI from $114 to $108. Piper Jaffray rated GSI as "overweight". Royal Bank of Canda also reduced their price target on GSI from $120 to $105. They set their rating of GSI at "outperform".
Jefferies Group reiterated a "hold" rating of Gilead Sciences Inc. and dropped their price target from $97 to $93. Robert W. Baird reiterated their "outperform" rating of GSIand dropped their price rating from $135 to $122. Credit Suisse Group AG reiterated their "buy" rating and dropped their price target from $120 to $115.
In all, ten issued research reports have Gilead Sciences as a "hold" rating and eighteen have the company at a "buy" rating. Two others have issued "strong buy" ratings to GSI. GSI has a consensus rating of "Buy" and a consensus target price of $103.78. GSI opened at 72.75 on Friday and their 200 day moving average price is $84.45. Their 50 day moving average price is $77.93.